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ABSTRACT.   
 
Heavy metals Arsenite (As3+) and Cadmium (Cd2+) are known human carcinogens 
and exposure to them occurs through cigarette smoking, industrialization, and 
contaminated water sources.  Epidemiological studies have shown that prolonged 
exposure to these heavy metals are associated with several health issues, including 
bladder cancer.  With survival rates directly correlated to detection age and tumor stage, 
the demand for early detection would effectively cut costs and improve the patient 
prognosis of human bladder cancer.  
Metallothioneins (MT) play an essential role in metal regulation, heavy metal 
detoxification, and cellular redox chemistry in cellular biological systems and tissues.  
Previous studies in literature have found elevated MT expression in patients with kidney, 
breast, prostate and bladder cancers.  This increased presence of MT may contribute to 
the resistance to the chemotherapy drug Cis-diamminediechloroplatinum(II), CDDP 
(Cisplatin) in human bladder cancer.   
Previous studies from our laboratory have shown that As3+ and Cd2+ can 
malignantly transform the human urothelial cell line UROtsa and these transformed cells 
can form subcutaneous, as well as, intraperitoneal tumors.  The first goal of this study is 
xivi 
 
to determine the expression level of six MT isoforms (MT-1A, MT-1E, MT-1F, MT-1X, 
MT-2A, and MT-3) in the Parent UROtsa cell line and the 13 independently derived 
As+3-and Cd+2-transformed cell lines.  The second goal of this study is to determine the 
expression levels of the same six MT isoforms in the Parent UROtsa and in two As+3 (As 
#1 and As #5) -and two Cd+2 (Cd #1 and Cd #4) -transformed cell lines when they were 
acutely exposed to various concentrations of the chemotherapy drug, cisplatin. 
For this study, Messenger Ribonucleic Acid (mRNA) was isolated from the 
Parent UROtsa cell line and the 13 independently derived As+3-and Cd+2-transformed cell 
lines, as well as, two As+3 (As #1 and As #5) -and two Cd+2 (Cd #1 and Cd #4) -
transformed cell lines and the Parent UROtsa after the cells were acutely exposed to 
cisplatin.  Real Time Reverse Transcriptase Quantitative Polymerase Chain Reaction 
(RT-qPCR) was performed to determine the basal expression of the six MT isoforms in 
the Parent UROtsa cell line and the 13 independently derived As+3-and Cd+2-transformed 
cell lines.  Real Time RT-qPCR was also performed to determine the corresponding 
expression of the Parent UROtsa and in two As+3 -and two Cd+2 -transformed cell lines 
after the cells were acutely exposed to cisplatin.  The results demonstrated an overall 
decrease in the expression of the six MT isoforms in the transformed cell lines compared 
to the Parent UROtsa, as well as, an overall decrease in expression after exposure to 
cisplatin when compared to the basal expression levels.    
In order to further look at the basal expression, Immunohistochemical (IHC) 
analysis was performed on the subcutaneous transplants generated by the subcutaneous 
injection of the 13 independently derived As+3-and Cd+2-transformed cell lines into 
immune compromised mice. The six As3+ and the seven Cd2+ UROtsa mouse 
xvi 
 
subcutaneous tumors were stained for MT isoforms 1/2 and MT isoform 3.  MT isoforms 
1/2 staining of the 13 UROtsa mouse subcutaneous tumors show moderate or weak-to-
moderate staining.  MT isoform 3 showed strong and diffuse staining, however the 
peripheral less differentiated tumor cells showed weaker staining.  
Additionally, western blot analysis was performed to determine the levels of MT 
proteins in the Parent UROtsa and two of the As3+ -and two of the Cd2+ -transformed cell 
lines.  Overall, the results demonstrated a decrease in the levels of total MT in the Parent 
UROtsa, as well as, the transformed cell lines.  
In conclusion, our data shows that exposure to As3+ or Cd2+ decreases the 
expression of the six MT isoforms.  This decrease in MT expression may disrupt the 
normal cellular redox within the cells, thus promoting the transformation process.  In 
addition, exposure to cisplatin demonstrated a decrease in expression of the six MT 
isoforms, which may have implications in the treatment of human bladder cancer with 
this drug.  
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CHAPTER I.  
 
INTRODUCTION. 
 
The Human Urinary System.   
 
The human urinary system is made up of organs, tubes, and muscles that regulate and 
eliminate toxic chemicals from the body using paired kidneys, paired ureters, urinary 
bladder, and urethra as the primary components (Zimmermann, 2018).  To maintain 
homeostasis the body relays the urinary system for filtration and excretion of urine (Ross & 
Pawlina, 2016). 
The human urinary bladder is a distensible reservoir for urine that is located in the 
pelvis and maintains three openings, two for the ureters and one for the urethra (Ross & 
Pawlina, 2016).  The urinary bladder has two important functions: storage of urine and 
emptying of urine (Andersson & Arner, 2004).  During urine storage the bladder retains low 
pressure, which contracts to high pressure during the emptying phase.  The detrusor smooth 
muscle is the main muscle component of the urinary bladder wall (Andersson & Arner, 
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2004).  During the process of urination the sphincters relax allowing urine to pass through the 
urethra (Urinary Retention, 2018). 
On average, adults filter and dispose of about one liter and a half of urine each day, 
which makes the human bladder a major site for prolonged chemical exposure (Keil, Berger-
Ritchie, & McMilin, 2011).  Urine retention can produce severe urinary infections, bacterial 
infections, and even advance into cancer that can affect the entire urinary system (Selius & 
Subedi, 2008). 
 
Environmental Background of Human Bladder Cancer. 
 
In 1895, the discoveries of Ludwig Rehn initiated the first connection between 
bladder cancer and environmental agents in Frankfurt, Germany (Rehn, 1895).  Rehn was 
attracted to the increasing prevalence of bladder cancer among workers in German dye 
manufacturer plants (Dietrich & Dietrich, 2001).  His studies initially targeted aniline as a 
potential source, which sparked the association of bladder cancer cases amongst industry 
workers.  This link established occupational toxicity as a mediator to bladder cancer.  Further 
studies into occupational toxicology exposed carcinogenic aromatic amines found in the 
production of rubber, textiles, and chemical consequences of industrialization (Johansson & 
Cohen, 1992).  In later years, naphthylamine and aromatic amines were also determined to be 
cancer-causing agents (Hueper, Wiley, & Wolfe, 1938).  Rehn was ultimately responsible for 
the investigation that lead to regulations to protect workers, which continues to intensify.  
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Despite robust worker protection laws in 2010 in among men, bladder cancer was still 
the sixth most common cancer (Jemal, Siegel, Xu, & Ward, 2010).  Harmful aromatic 
amines, unsaturated aldehydes, and Cd2+ are known cancer-causing agents that are still 
present in cigarettes.  It is estimated that there is a three times higher risk for bladder cancer 
in smokers verse non-smokers (Zeegers, Tan, Dorant, & Van Den Brandt, 2000).  Smokers 
are exposed to known cancer-causing agents at a rate of 1.7 µg of Cd2+ and 1.4 µg of As3+ 
per cigarette (ATSDR, 2012) (Smith, Livington, & Doolittle, 1997).  Elevated and 
reoccurring exposure to As3+ and Cd2+ via cigarette smoking is a confirmed risk factor of 
bladder cancer (Freedman, Silverman, Hollenbeck, Schatzkin, & Abnet, 2011).  
 
Bladder Cancer Prevalence.   
 
 Today bladder cancer is the sixth most common cancer in men and the 17th most 
common cancer in women the United States (Bladder Cancer Statistics, 2018).  Bladder 
cancer is also the tenth most common cancer worldwide (Bladder Cancer Statistics, 2018).  
In 2014, the Center for Disease Control and Prevention (CDC) estimated 72,462 people 
(55,014 men and 17,448 women) were living with bladder cancer, and 15,775 (11,291 men 
and 4,484 women) deaths were due to the disease.  Statistically, bladder cancer is more 
common among Caucasians (whites), and three times more likely in men verse women.  The 
American Cancer Association (ACS) estimates that 9 out of 10 people with bladder cancer 
are over the age of 55 years old, with the average diagnosis at 73 years old.  
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 The annual cost of bladder cancer was about $4 billion in the United States, when 
estimated in 2010, and it is predicted to rise to about $5 billion by 2020 (Yeung, Dinh, & 
Lee, 2014).  Bladder cancer poses a significant economic burden due to required lifetime 
surveillance, treatment for reoccurring tumors, and the overall cost associated with treatment 
and patient care (Jacobs, Lee, and Montie, 2010).   
Over the last decade, several advances have been made in the diagnosis and treatment 
of human bladder cancer.  Research and development continues to strive for expansion of 
molecular understanding, early detection biomarkers, and improvement of technology such 
as florescent cystoscopy (Jacobs, Lee, and Montie, 2010).  
 
Arsenite Causes Human Bladder Cancer. 
 
As3+ is a metalloid that has both metal, as well as, non-metal properties and has been 
classified by the International Agency for Research on Cancer (IARC) as a human 
carcinogen.  It has also been evaluated and determined to be hazardous by The 
Comprehensive Environmental Response, Compensation, and Liability Act, also known as 
CERCLA.  CERCLA’s Priority List of Hazardous Substances by the Agency ranked As3+ 
first in 2007 for Toxic Substances and disease Registry (2007 CERCLA Priority List of 
Hazardous Substances, 2018).  Studies show that tens of millions of people are exposed 
worldwide to As3+ and have concluded it is a well-established cause of lung and bladder 
cancer (Steinmaus, et al., 2014).  In addition to lung and bladder cancer, oral ingestion of 
inorganic As3+ is known to cause skin, kidney, liver, and prostate cancer (ATSDR, 2007).    
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As3+, a ubiquitous metalloid, can exist in both organic and inorganic forms (Mandal 
& Suzuki, 2002).  Organic forms of As3+ are associated with carbon (C) and hydrogen (H), 
while inorganic forms are associated with iron (Fe) , cobalt (Co) or nickel (Ni) coupled with 
sulfide (S2-) minerals (Bhattacharya, et al., 2007).  Inorganic As3+ are released into the 
environment from anthropogenic sources, including both naturally and through human 
intervened routes.  The most notorious exposure routes are metal mining and smelting, 
pesticide use, wood combustion, as well as, waste combustion (Jang, Somanna, & Kim, 
2016) (ASTDR, 2007).  As3+ released from the soil can be absorbed into ground water.  The 
most common general route of human exposure to As3+ is through contaminated drinking 
water (Chiou, et al., 1995). 
Millions of people worldwide are exposed to naturally occurring As3+ in their 
drinking water (Steinmaus, et al., 2013).  Bladder cancer was first investigated in Taiwan, as 
a result to high incidence of Blackfoot disease (BFD) (Tseng, 1997).  BFD is a severe form 
of peripheral vascular disease (PVD), in which the blood vessels in the lower limbs are 
severely damaged, resulting eventually in progressive gangrene due to As3+ exposure (Tseng, 
et al., 2005).  It was most common among farmers in the region tending to their crops 
(Arsenic, 2018).  Studies all around the world have deliberated the effects of As3+ in BFD 
and other various cancers.  Many studies have attempted to calculate the maximum 
containment level (MCL) for the United States that regulates the concentration of As3+ that 
the public is exposed to (Marshall, et al., 2007).  As3+ has more effects on health than any 
other toxicant, and the list continues to grow, along with evidence that exposure is 
widespread throughout the world (Smith & Steinmaus, 2011).  
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Cadmium Causes Human Bladder Cancer. 
 
Cd2+ is a heavy metal that has been classified by the IARC as a human carcinogen.  
Cd2+ has also been specifically studied to have an association with the development of human 
bladder cancer (Siemiatycki, Dewar, & Gerin, 1994).  Cd2+ is naturally found in the earth’s 
crust and throughout volcanic emissions, as well as, forest fires and other natural 
phenomena’s (Cadmium, 2018).  Additionally, lettuce, spinach, potatoes, peanuts, soybeans, 
and sunflower seeds are very high sources of natural occurring Cd2+ (ATSDR, 2012). 
National Toxicology Program (NTP) listed that human exposure to Cd2+ is mainly 
through diet, industrial hazards, and cigarette smoking (NTP, 2011).  Occupational exposure 
is very high among smelting, welding, and other various jobs that produce Cd2+ powder 
(NTP, 2011).  Man-made application are the main source of toxic Cd2+ release in the 
environment.  The estimated Cd2+ intake is 0.35 µg/kg/day in males and 0.30 µg/kg/day for 
females, which is roughly 1:5 over the daily limit by smoking a single cigarette (Choudhury 
et al., 2001).  Cd2+ exposure poses a great health risk to humans since the metal is unable to 
be metabolized into a less toxic form, while also being poorly secreted due to its long half-
life (Satarug & Moore, 2004). 
 Cd2+ accumulation in the tissues was first studied in 1955 in Japan.  The outbreak of 
Itai-Itai Disease connected contaminated rice paddies, which was the main source of food for 
residents in the area, to Cd2+ (Inaba, et al., 2005).  The disease translates to “it hurts-it hurts” 
which is fitting due to renal injury due to tubular and glomerular dysfunction, followed by 
bone injury consisting of osteoporosis.  The toxicity rigorously spread throughout the body in 
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parallel with severe pain, ultimately leaving the patients bed-ridden (Biggers & Paddock, 
2018).  
Cd2+ was also intensely studies in northeastern Belgium and southeastern Netherlands 
due to an established correlation between long term emission of Cd2+ by Zn smelters and 
human bladder cancer.  Cd2+ is an established carcinogen linked to many cancers but the 
manner by which Cd2+ causes each cancer is not fully elucidated yet.  
 
Arsenite and Cadmium Transformed UROtsa Cells. 
 
The UROtsa cell line originated from urothelial cells derived from the left ureter of a 
12-year-old girl.  After extraction the cells were immortalized with a temperature sensitive 
Simian Virus 40 (SV40) large tumor-antigen (T-antigen) gene.  Commercially available 
immortalized human bladder cancer-derived cell lines are well characterized but do not allow 
for initial stages of carcinogenesis to be effusively investigated.  The UROtsa cell 
morphology aligns with primary urothelial cells growing in tightly packed colonies allowing 
investigation into the preliminary phase of development (Rossi, et al., 2001).  
 Our laboratory has exposed the immortalized UROtsa cell line to As3+ or Cd2+ in 
order to establish an in-vitro cell culture model that is representative of the mechanisms 
involved in early bladder cancer.  Our laboratory strategically exposed non-tumorigenic 
urothelial cell line, UROtsa, to long term As3+ or Cd2+ with the endpoint goal of the cells able 
to form colonies in soft agar and form tumors when heterotransplanted into nude mice (Sens, 
et al., 2004).  
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During the transformation, the cells were injected into the nude mice to evaluate 
tumor formation.  Nude mice are a laboratory mouse strain with a genetic mutation that 
causes an inhibited immune system response and are universally recognized as 
immunocompromised mice.  They are the ideal mouse strain for rapidly growing tumor 
models since they can receive many different types of tissue and/or tumor grafts without 
mounting a rejection response.  Their hairless nature is also ideal because they do not need to 
be shaved (Inbred & Outbred Nude Mice, 2018).  
The histology of the tumors produced features consistent with those of classic 
transitional-cell carcinoma (TCC) of bladder cancer.  The heterotransplant tumors displayed 
prominent squamous differentiation.  Long-term in-vitro exposure causes As3+ and Cd2+ to 
malignantly transform urothelial cells as indicated by anchorage independent cell growth and 
tumor formation in nude mice (Sens, et al., 2004).   
 
Metallothioneins. 
 
Through cysteine residues, MT play an important role in detoxification by uptake, 
transport, and regulation of metals in biological systems (Mididoddi, McGuirt, Sens, Todd, & 
Sens 1995).  In both mice and humans, there are four classes of comparable MT proteins 
(Garrett, et al., 1999).  MT isoform 1, MT isoform 2, MT isoform 3, and finally MT isoform 
4, are defined in literature based on sequence and characteristics.  MT are a family of 
cysteine-rich metal binding antioxidant proteins in humans consisting of 10 functional and 
seven non-functional isoforms.  Of the 10 functional there are seven functional MT isoform 
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1’s and one functional gene for MT isoform 2, MT isoform 3, and MT isoform 4 respectively 
(Liu, et. al., 2007).  Within the MT isoform 1 there are seven functional isoforms.  For this 
study we choose to examine four (MT-1A, MT-1E, MT-1F, and MT-1X).  Within MT 
isoform 2 there is one function isoform, MT isoform 2A, which was also used throughout 
this study.  MT isoform 3 has one functional isoform that was looked at in this study because 
it exhibits tissue-specific expression specifically differentiating this isoform from the 
ubiquitously expressed MT isoform 1 and MT isoform 2.   
MT isoform 1 and MT isoform 2 are ubiquitously expressed at high levels, while MT 
isoform 3 and MT isoform 4 exhibit more restricted tissue specific expression.  MT isoform 1 
and MT isoform 2 have been extensively studied and are believed to serve an important role 
in the homeostasis of essential metals such as Zn2+ and Cu2+ during growth and development.  
MT isoform 1 and MT isoform 2 are also important in the detoxification of heavy metals, 
such as Cd2+ and Hg2+ (Sens, et al., 2000).  Typically MT isoform 3 and MT isoform 4 
exhibit more restricted tissue specific expression, with the highest distributions classically 
recognized to localize to the CNS and stratified epithelium, respectively. 
MT are localized to the membrane of the Golgi apparatus with the capacity to bind 
when metal absorption levels are elevated (Chabin-Brion, et al., 2001).  MT are most well-
known for its binding affinity with zinc (Zn), copper (Cu), selenium (Se), mercury (Hg), and 
other heavy metals like As3+ or Cd2+ (Smith, et al., 2006).  MT proteins range from 500 to 
14000 Da (5- 14 kDa) in size with 61 to 68 amino acids that remain highly conserved 
primary and secondary structures across the isoforms (Isani & Carpené, 2014).   
While the role of MT in cancer development is still largely unknown, their induction 
due to heavy metals may be a mediator to cisplatin resistance.  At the cellular level MT 
10 
 
respond to the presence of cisplatin to trap the central platinum (Pt) element (Hagrman, 
Goodisman, Dabrowiak, & Souid, 2003).  The continued presence of cisplatin causes an 
upregulated levels of MT, glutathione (GSH), and other cellular thiols, which increase the 
cell’s resistance to cisplatin (Hagrman, Goodisman, Dabrowiak, & Souid, 2003).  There is 
currently very little kinetic data evaluating the relationship between cisplatin and MT.  
 
The Chemotherapy Drug Cisplatin. 
 
 Figure I-1.  The Cisplatin Drug Structure.  
 Cisplatin is an anti-cancer chemotherapy  
 drug (Cisplatin, 2018).   
 Pt: Platinum, Cl: Chlorine, NH3: Ammonia.  
  
Cisplatin is a small heavy metal complex that reacts with two different sites on 
Deoxyribonucleic Acid (DNA) leading to the inhibition of synthesis and transcription 
(Gonzalez, Fuertes, Alonso, & Perez, 2001).  Cisplatin, like shown above in Figure I-1, is a 
central Pt containing anti-cancer drug used to treat not only bladder cancer, but a variety of 
cancers, including lung, cervical, testicular and ovarian, just to mention a few (Shaloam & 
Tchounwou, 2015).  Unfortunately, this methods it is not always effective since most cancers 
eventually acquire a resistance to cisplatin following long-term treatment making it a critical 
target for research.  This high probably of developing resistance has a huge medical burden 
(Oliver, 2010).   
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Cisplatin is an anti-cancer chemotherapy drug that exerts its antitumor activity by 
binding to cellular DNA (Gelasco & Lippard, 1998).  When cisplatin enters the cell, it passes 
through the cytosol and crosses the nuclear membrane where it binds to nitrogen (N) atoms 
on the bases of DNA.  When the cisplatin is bound to the DNA it prevents the double helix 
structure of DNA from linearizing.  DNA must be linear into order to be transcribed, 
therefore cell death is prompted via apoptosis (Ferguson & Baguley, 1994).  This ultimately 
leads to a reduced tumor size as a result of successful treatment with cisplatin.  
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Statement of Purpose. 
 
Previous studies from our laboratory established that the 13 independently derived 
As+3 -and Cd+2 -transformed cell lines are an ideal model system to study TCC or urothelial 
carcinomas.  The first goal of this study is to determine the basal expression level of the six 
MT isoforms (MT-1A, MT-1E, MT-1F, MT-1X, MT-2A, and MT-3) in the Parent UROtsa 
and the 13 independently derived As+3 -and Cd+2 -transformed cell lines.  The second goal of 
this study is to determine the expression levels of the same six MT isoforms in the Parent 
UROtsa, as well as, two As+3 (As #1 and As #5) -and two Cd+2 (Cd #1 and Cd #4) -
transformed cell lines when they are acutely exposed to various concentrations of the 
chemotherapy drug, cisplatin.  MT are a well-known and highly studied cysteine-rich, low 
molecular weight family of intracellular proteins that bind to heavy metals with high affinity.  
MT expression may disrupt the normal cellular redox within the cells, thus promoting the 
transformation process.  In many cancers, there is evidence suggesting that increased 
expression of MT correlates to cisplatin resistance and poor patient prognosis.  
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CHAPTER II.   
 
Materials And Methods. 
 
The UROtsa Cell Line Immortalization and Culturing. 
 
The immortalization and culturing of the human urothelial UROtsa cell line was 
previously described in (Rossi, et al., 2001).  In short, the UROtsa cells were maintained 
at 37.0˚C in a 5.0% carbon dioxide (CO2) and 95.0% atmosphere oxygen (O).  UROtsa 
cells were grown in 75.0 cm2 certified cell culture flasks with Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Gibco #311320033), supplemented with 5.0% volume-
volume percent of fetal calf serum (FCS) (Gibco #10437010).  Once the cells reached 
confluency, the cells were passaged at a 1:3 ratio with 0.25% Trypsin/EDTA, phenol red 
(Gibco #25200114).  Growth media was fed to the cells every three days. 
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Arsenite and Cadmium Malignant Transformation. 
 
 The immortalized urothelial UROtsa cells were malignantly transformed with 
As3+ and Cd2+ as previously described in (Sens, et al., 2004).  In short, following the 
identical cell culturing protocol the cells were transformed with 1.0 µM cadmium 
chloride (CdCl2) (Sigma-Aldrich #7440-23-5), as well as, 1.0 µM sodium arsenite 
(NaAsO2) (Sigma-Aldrich #S7400-100G).  During the transformation, the cells were 
intermittently tested in order to establish if there was successful colony formation.  
Colony formation was tested by performing soft agar assays to determine anchorage 
independent growth.  There was six As3+ and seven Cd2+ isolates were expanded 10 times 
at a 1:10 ratio before protocol use.  The transformed cells were maintained in DMEM 
supplemented with 5.0% volume-volume percent of FCS and 1.0% glucose.  Further 
subculturing was performed at a 1:10 ratio.  All As3+ and Cd2+ isolates were able to form 
colonies in soft agar as described in (Sens, et al., 2004). 
 
UROtsa Exposed to Cisplatin Set-up. 
 
The cells were cultured identical to urothelial UROtsa protocol before treatment 
with cisplatin (Sigma Aldrich #NC0837572).  Cisplatin was dissolved in 5.0% molecular 
grade water (H2O) and 95.0% sodium chloride (NaCl) prior to sterilization.  The stock 
was further diluted to achieve the desired concentrations with the 1:19 ratio diluent.  
Cisplatin treatment doses of 0.5 µM and 1.0 µM were added to the cultures when cells 
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were confluent, and the cells were maintained for Day #1 (24-hours) and Day #2 (48-
hours) in 25.0 cm2 certified cell culture flasks.  In order to determine the growth effects 
of exposure to cisplatin on the Parent UROtsa and two As3+ (As #1 and As #5) -and two 
Cd2+ (Cd #1 and Cd #4) -transformed cell lines MTT assays were performed.  Cell 
viability was assessed using 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
Bromidefor (MTT) assays 3.5 hours after treatment to quantify the cells sensitivity to the 
cisplatin.  Cells were seeded in 6-well plates and allowed to grow for up to six days.  
Plates of cells were taken daily and exposed to 100.0 mg/mL MTT (Sigma-Aldrich, St. 
Louis, MO; M5655) for 3.5 hours.  Cells were then rinsed twice with phosphate buffered 
saline and then with 1.0 mL acidic propanol.  Optical density was evaluated at 570.0 nm 
and data was used to calculate doubling times for each cell line.  After Day #1 (24-hours) 
and Day #2 (48-hours), the cells were harvested for protocol use.   
 
Immunohistochemistry Analysis.  
 
 Tissue samples were fixed in 10.0 % neutral-buffered formalin for 16 - 18 hours.  
All tissues were then transferred to 70.0 % ethanol and dehydrated in 100.0 % ethanol.  
The dehydrated tissues were cleared in xylene, infiltrated, and embedded in paraffin.  
Serial sections of subcutaneous tumors cut at 3.0 - 5.0 µm were used for IHC.  Prior to 
immunostaining, tissue sections were immersed in preheated Target Retrieval Solution 
(Dako, Carpinteria, CA) and heated in a steamer for 20.0 minutes.  The sections were 
allowed to cool for 30.0 minutes at room temperature and immersed in TBS-T for 5.0 
minutes.  The primary antibodies were localized at room temperature for 30.0 minutes 
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liquid diaminobenzidine (Dako) was used for visualization.  Counter staining was 
performed for 8.0 minutes at room temperature using Ready-to-use Hematoxylin (Dako).  
The major steps are listed below in Table II-1.   
 
Table II-1.  Major Steps for Immunohistochemical Staining. 
Target Retrieval Solution  20.0 Minutes 
Tris-Buffered Saline with 1.0% Tween  5.0 Minutes 
Primary Antibody Incubation 30.0 Minutes 
Visualization with 3,3'-Diaminobenzidine (DAB) 10.0 Minutes 
Counterstaining with Hematoxylin 8.0 Minutes 
 
The primary antibody used are listed below in Table II-2.  Next, the slides were 
rinsed with Distilled water, dehydrated in molecular grade ethanol, cleared in xylene 
before the coverslip was set.  Certified Pathologist at the University of North Dakota 
School of Medicine and Health Sciences then examined it.  
 
Table II-2.  Antibody used for Immunohistochemistry Analysis. 
Antibody Dilution Source & Clonality Storage Company Catalog # Mw (kDa) 
MT, E9 
1:200 
(BSA) 
Mouse 
Monoclonal 
-20˚C 
DAKO 
(Agilent) 
M0639 6 
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Protein Isolation. 
 
 Total protein was isolated from pellets stored at -80˚C.  Protein samples were 
lysed in cold Radioimmunoprecipitation Assay Buffer (RIPA) buffer containing 10.0 µL 
protease inhibitor, 10.0 µL phenylmethane sulfonyl fluoride (PMSF), and 10.0 µL 
sodium (Na) orthovanadate (Santa Cruz #24948).  Cell pellets were resuspended and 
incubated on ice for 30.0 minutes on the orbital shaker in the 4˚C refrigerator.  The 
extracts were sonicated and then centrifuged at 13,200 relative centrifugal force (rcf) for 
10.0 minutes at 4˚C.  Supernatant was transferred to a cold microfuge tube and the 
protein concentration was determined through Bicinchoninic Acid Assay (BCA) (Pierce 
#23228 & #1859078).  
For each BCA Assay the dye reagent was prepared by adding 500.0 µL of reagent 
“B” to 25.0 mL of Reagent “A.”  The reagents were mixed by inverting the falcon tube 
several times.  Next 2.0 mg/mL of Stock of Albumin Standard (Thermo Fisher #23209) 
was serial diluted to create standards for the assay.  The standards are listed below in 
Table II-3.  The standards created markings for more accurate calculations of the total 
sample protein concentration.  In the 96-well plate 200.0 µL dye and 10.0 µL sample 
protein was added per well.  Once all standards and samples were added the plate was 
covered with saran wrap and incubated for 30.0 minutes @ 37˚C.  After incubation the 
plate absorbance was read at 570.0 nm.  The absorbance was then calculated through 
GraphPad Prism® (Version 7.02) protocol to determine the concentration of the proteins. 
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Table II-3.  BCA Assay Standard Concentrations. 
Tube Volume of Diluent Volume of BSA 
Final 
Concentration 
A 0.0 µL 300.0 µL of Stock 2,000 µg/mL 
B 125.0 µL 375.0 µL of Stock 1,500 µg/mL 
C 325.0 µL 325.0 µL of Stock 1,000 µg/mL 
D 175.0 µL 175.0 µL of vial B dilution 750 µg/mL 
E 325.0 µL 325.0 µL of vial C dilution 500 µg/mL 
F 325.0 µL 325.0 µL of vial E dilution 250 µg/mL 
G 325.0 µL 325.0 µL of vial F dilution 125 µg/mL 
H 400.0 µL 100.0 µL of vial G dilution 25 µg/mL 
 
Real Time Reverse Transcriptase Quantitative Polymerase Chain Reaction. 
 
Total mRNA was isolated from cell pellets using the TRI Reagent® Protocol 
(Molecular Research Center, Inc.).  mRNA was quantified by spectrophotometry 
(Thermo Fisher NanoDrop One).  Then 100.0 ng of isolated mRNA was subjected to 
complementary DNA (cDNA) synthesis using iScript cDNA Synthesis Kit (BioRad 
#170-8891); total volume of 20.0 µL. Real Time RT-qPCR was performed using 10.0 ng 
of cDNA with iTag Universal SYBR Green Supermix (BioRad #172-5124).  Then 0.2 
µM primers in total volume of 20.0 µL were used in a CFX real-time detection system 
(BioRad #CFX96).  Amplification was monitored by SYBR green fluoresces and 
analyzed by interpolation from a quantitative standard curve created from serial dilutions.  
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Cycling parameters included a 5.0-minute hot start followed by 40.0 cycles of 
denaturation at 95˚C (30.0 seconds), annealing at 60˚C (30.0 seconds), and extension at 
72˚C (30.0 seconds).  Confirmation of dominate double stranded species was 
demonstrated by appropriate denaturation temperature by melt curve analysis.  Primers 
used are indicated below in Tables II-4 and II-5. 
 
Table II-4.  Invitrogen Primer Pairs for Real Time RT-qPCR Analysis. 
MT-1A 
Product: 219 bp 
Upper 5’ CTCGAAATGGACCCCAACT 
Lower 5’ ATATCTTCGAGCAGGGCTGTC 
MT-1E 
Product: 284 bp 
Upper 5’ GCTTGTTCGTCTCACTGGTG 
Lower 5’ CAGGTTGTGCAGGTTGTTCTA 
MT-1F 
Product: 232 bp 
Upper 5’ AGTCTCTCCTCGGCTTGC 
Lower 5’ ACATCTGGGAGAAAGGTTGTC 
MT-1X 
Product: 151 bp 
Upper 5’ TCTCCTTGCCTCGAAATGGAC 
Lower 5’ GGGCACACTTGGCACAGC 
MT-2A 
Product: 259 bp 
Upper 5’ CCGACTCTAGCCGCCTCTT 
Lower 5’ GTGGAAGTCGCGTTCTTTACA 
MT-3 
Product: 325 bp 
Upper 5’ CCGTTCACCGCCTCCAG 
Lower 5’ CACCAGCCACACTTCACCACA 
 
Table II-5.  Other Primers Used for Real Time RT-qPCR Analysis. 
Gene Company Catalog Number 
Beta Actin (β-Actin) BioRad qHsaCEP0036280 
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Statistical Analysis. 
 
 Statistical analyses were completed using GraphPad Prism® (Version 7.02).  
Through this software, separate variance t-tests, one-way analysis of variance (ANOVA) 
with Tukey or Dunnett’s post-hoc tests were performed with 0.05 significance.  All real 
time RT-qPCR results were executed in triplicate and express the standard error of the 
mean (SEM). 
 
Metallothionein Western Blot Analysis. 
 
For western blot analysis protein lysates were mixed with 2X Laemmli Buffer 
(BioRad #161-0737) containing 5.0 % beta-mercaptoethanol (β-mercaptoethanol) 
(BioRad #161-0710) and boiled for 5.0 minutes at 95˚C to reduce and denatured the 
protein.  Equal volumes containing 30.0 - 50.0 µg of total protein were loaded onto 4.0 -
20.0 % gradient gels (BioRad #456-8093).  The proteins were then transferred to 0.2 µm 
Polyvinylidene Difluoride (PVDF) membranes (BioRad #170-4156) using the standard 
protocol for semi dry 30.0-minute Trans-blot Turbo transfer at 25.0 volts (V) and 1.0 
ampere (AMP).  Following transfer, the membrane was incubated in 2.5% glutaraldehyde 
(Sigma #G7651-10) allowing the cross linking of the proteins to the membrane for 60.0 
minutes.  The membranes where then blocked in 3.0% Bovine Serum Albumin (BSA) 
(Fisher Scientific #BP1605-100) dissolved in 10.0 mM Tris-Buffered Saline (TBS) 
(BioRad #170-6435) on the orbital shaker at room temperature for 120.0 minutes.  The 
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membranes where then washed in 10.0 mM TBS and 1.0% Tween-20 (TBS-T) (Sigma 
#P1379-500) before the overnight (16.0 hours) incubation of the primary antibody.  After 
the membranes were washed in TBS-T there were incubated for 90.0 minutes in the 
secondary antibody on the orbital shaker at room temperature.  Blots were visualized 
using Clarity Western ECL Substrate (BioRad #170-5061). 
 
Table II-6.  Primary Antibodies used for Metallothionein Western Blot Analysis. 
Antibody Dilution Source & Clonality Storage Company Catalog # Mw (kDa) 
MT, E9 
1:200 
(BSA) 
Mouse 
Monoclonal 
-20˚C 
DAKO 
(Agilent) 
M0639 6 
β-Actin 
1:5000 
(BSA) 
Mouse 
Monoclonal 
-20˚C Abcam Ab8226 42 
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CHAPTER III.  
 
Experimental Results. 
 
Arsenite and Cadmium In-vitro Model System.   
 
In order to study the mechanisms involved in early bladder cancer our laboratory 
strategically exposed the non-tumorigenic urothelial cell line UROtsa to long term treatment 
with As3+ or Cd2+ with the endpoint goal to determine if these heavy metals were capable of 
causing malignant cell transformation.  The metal treated cells demonstrated a loss of the 
ability to stratify at confluency when compared to the Parent UROtsa, as well as, higher 
growth rates were also seen in the 1.0 µm As3+ or Cd2+ treated cells.   
In order to further evaluate if these cells were able to cause malignant transformation 
they were plated on soft agar before being injected into nude mice.  When plated the 
transformed cells showed colony formation, an indicator of anchorage independent growth.  
Additionally, the cells formed tumors when injected into nude mice.  The histology of the 
tumors produced features consistent with those of classic TCC of bladder cancer.  The 
heterotransplant tumors displayed prominent squamous differentiation.  Therefore the 
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malignantly transformed UROtsa cell lines are an ideal model for studying bladder cancer.  
More details and all cell culture methods as described in the Methods and Materials.  Cell 
culture media, buffers, and solution recipes are in Appendix B.  
 
Real Time Reverse Transcriptase Quantitative Polymerase Chain Reaction. 
 
 Real time RT-qPCR analysis was performed on most of the MT isoforms (MT-1A, 
MT-1B, MT-1E, MT-1F, MT-1G, MT-1H, MT-1J, MT-1L, MT-1M, MT-1X, MT-2A, MT-
3, and MT-4) however not all were continually used throughout the project.  The MT 
isoforms that were focused on in this project are listed below in Table III-1, along with each 
isoforms corresponding size in base pairs.  
All data was derived in an absolute fashion.  Each standard curve was derived from 
serial dilution of the known purified PCR product at 108 transcripts stock of the target gene.  
The real time RT-qPCR was also normalized to Beta-Actin (β-Actin), which is a gene that is 
highly expressed in all cell types and is a known house-keeping gene.  We know that a 
threshold cycle (Ct) value for β-Actin is roughly equal to 2.0 x 106 transcripts.  The Ct is 
defined as the cycle number at which fluorescence generated within a reaction exceeds that 
of the background and is inversely proportional to the expression.  For clarification the lower 
the Ct value the higher the gene expression.  More details on real time RT-qPCR as described 
in the Methods and Materials.  A brief introduction to real time RT-qPCR and extended 
explanation of Ct are found in Appendix C.  
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Table III-1.  Metallothionein Isoforms evaluated in this Project.   
The table below shows the MT isoforms that were used throughout this project.  The table 
also shows the base pairs that correspond with each isoform.  
 
Table III-1.  Metallothionein Isoforms evaluated in this Project.   
MT Isoforms Base Pairs 
MT-1A 219 
MT-1E 284 
MT-1F 232 
MT-1X 151 
MT-2A 259 
MT-3 325 
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Basal Expression of Metallothioneins in the UROtsa Cell Lines. 
 
The Parental UROtsa, six independent As3+ -transformed cell lines and seven 
independent Cd2+ -transformed cell lines, were assessed for their basal expression levels of 
the six MT isoforms (MT-1A, MT-1E, MT-1F, MT-1X, MT-2A, and MT-3).  MT isoform 
1A showed the Parent UROtsa cells displayed at a higher expression when compared to the 
minimal expression of the six independent As3+ cell lines and seven independent Cd2+ cell 
lines of the transformed cells (Figures III-1 and III-2, respectively).  All 13 cell lines 
exhibited similar statistically significant expression compared to the Parent UROtsa.  
For MT isoform 1E the expression was higher in the Parent UROtsa cells when 
compared to the As+3-transformed cell lines (Figure III-3).  This increase was statistically 
significant.  The expression pattern was similar for the Cd+2-transformed cell lines with the 
exception of Cd #7, which had increased expression when compared to the Parent UROtsa 
cells (Figure III-4).  
The expression of MT isoform 1F was decreased in the As+3-transformed cells when 
compared to the Parental UROtsa cells with one exception.  The exception was As #4, which 
showed increased expression when compared to the Parental UROtsa cells.  All expression 
changes were statistically significant (Figure III-5).  For the Cd+2-transformed cell lines, the 
expression of MT isoform 1F was decreased in three of the cell lines Cd #1, Cd #5, and Cd 
#6.  Whereas the expression was increased compared to the Parent UROtsa cell line for Cd 
#7 (Figure III-6).  There was no change in expression of MT isoform 1F in Cd #2, Cd #3, and 
Cd #4.   
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The expression of MT isoform 1X was similar between the Parent UROtsa and the 
As+3 -transformed cell lines with the exception of As #4, which had a higher expression 
compared to the Parent UROtsa.  This increase in expression was statistically significant 
(Figure III-7).  The expression of MT isoform 1X in the Cd+2 -transformed cell lines was 
similar in five of the seven transformed cell lines.  For Cd #1 and Cd #7, the expression of 
MT isoform 1X was higher compared to the Parent UROtsa cells.  This increase was also 
statistically significant (Figure III-8).  Albeit the expression of MT isoform 1X was lower in 
the Cd #5 when compared to the Parent UROtsa, this decrease was not statistically 
significant.  
The expression of MT isoform 2A was decreased in the all of the As+3-transformed 
cell lines when compared to the Parent UROtsa cells.  The decreased expression in all of the 
As+3-transformed cell lines was statistically significant (Figure III-9).  The Cd2+-transformed 
cells showed decrease in expression of MT isoform 2A when compared to the Parent UROtsa 
in all of the cell lines with one exception.  The exception being Cd #7, which showed an 
increase in expression compared to the Parental UROtsa cells.  These expression levels were 
all statistically significant excluding Cd #7 (Figure III-10).  
The expression of MT isoform 3 was very low in the Parent UROtsa, as well as, the 
transformed cell lines.  There was a slight increase in As #1, As #2, As #3, As #4, and As #6, 
which were all statistically significant (Figure III-11).  For the Cd+2-transformed cells, the 
expression of MT isoform 3 was increased in Cd #1, Cd #3, Cd #5, and Cd #7 compared to 
the Parent UROtsa cells, while Cd #2, Cd #4, and Cd #6 showed similar expression to the 
Parent  UROtsa (Figure III-12).   
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In summary, the expression of the MT isoforms in the As3+ -and Cd2+ -transformed 
cell lines is lower than that of the Parent UROtsa with a few exceptions.  However, the 
expression of MT isoform 3 is very low in the Parent UROtsa as well as the As3+ -and Cd2+ -
transformed cell lines as seen previously in literature.   
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Figure III-1.  Expression of MT-1A in Parent UROtsa and As3+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 1A mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the As3+ -transformed cell lines. 
 
Figure III-2.  Expression of MT-1A in Parent UROtsa and Cd2+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 1A mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the Cd2+ -transformed cell lines.  
 
      
 
For statistically significant changes in comparison to the Parent UROtsa. 
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Figure III-3.  Expression of MT-1E in Parent UROtsa and As3+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 1E mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the As3+ -transformed cell lines. 
 
Figure III-4.  Expression of MT-1E in Parent UROtsa and Cd2+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 1E mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the Cd2+ -transformed cell lines.  
 
       
 
For statistically significant changes in comparison to the Parent UROtsa. 
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Figure III-5.  Expression of MT-1F in Parent UROtsa and As3+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 1F mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the As3+ -transformed cell lines. 
 
Figure III-6.  Expression of MT-1F in Parent UROtsa and Cd2+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 1F mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the Cd2+ -transformed cell lines.  
 
            
         
For statistically significant changes in comparison to the Parent UROtsa. 
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Figure III-7.  Expression of MT-1X in Parent UROtsa and As3+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 1X mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the As3+ -transformed cell lines. 
 
Figure III-8.  Expression of MT-1X in Parent UROtsa and Cd2+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 1X mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the Cd2+ -transformed cell lines.  
 
      
         
For statistically significant changes in comparison to the Parent UROtsa. 
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Figure III-9.  Expression of MT-2A in Parent UROtsa and As3+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 2A mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the As3+ -transformed cell lines. 
 
Figure III-10.  Expression of MT-2A in Parent UROtsa and Cd2+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 2A mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the Cd2+ -transformed cell lines.  
 
       
         
For statistically significant changes in comparison to the Parent UROtsa. 
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Figure III-11.  Expression of MT-3 in Parent UROtsa and As3+ Transformed Cell Lines.  
Real time RT-qPCR analysis of MT isoform 3 mRNA levels.  The mRNA levels were 
normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the Parent 
UROtsa and the As3+ -transformed cell lines. 
 
Figure III-12.  Expression of MT-3 in Parent UROtsa and Cd2+ Transformed Cell 
Lines.  Real time RT-qPCR analysis of MT isoform 3 mRNA levels.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ± SEM (n = 3) for the 
Parent UROtsa and the Cd2+ -transformed cell lines.  
 
       
 
For statistically significant changes in comparison to the Parent UROtsa. 
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Immunohistochemistry Analysis Expression of Metallothioneins 1/2 and 3. 
 
 IHC staining was used to determine the localization of MT isoforms 1/2 and MT 
isoform 3 in the cells of the mouse heterotransplant tumors.  IHC was performed in the 
histology core facility within the Department of Pathology by Dr. Xu Dong Zhou and the 
department technicians.  Tissue sections for IHC analysis were prepared and visualized as 
described in the Methods and Materials.  
MT isoforms 1/2 is an antibody that encompasses all the MT isoform 1 and MT 
isoform 2 since the genetic sequences are too similar to have two separate antibodies.  MT 
isoforms 1/2 staining of the six As3+ and the seven Cd2+ UROtsa Subcutaneous Tumors show 
moderate or weak-to-moderate staining in all of the isolates.  Only one tumor stained weakly 
positive for MT isoforms 1/2.  The percentage of the positive staining ranges from 5.0% to 
25.0%.  Usually, it is the less differentiated basal-like cells in the invading border or 
periphery of tumor nests that are positive for MT isoforms 1/2.  One tumor also shows strong 
positive MT isoforms 1/2 staining in the spindle tumor stroma cells (Figures III-13 and III-
14).  
All of the 13 UROtsa mouse subcutaneous tumors show strong and diffuse staining of 
MT isoform 3.  However, in some tumors, the peripheral less differentiated tumor cells show 
weaker staining.  Some tumor stroma cells are also positive for MT isoform 3, but the keratin 
pearls are negative.  The percentage of the positive staining ranges from 60.0% to more than 
80.0% (Figures III-15 and III-16). 
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Figure III-13, A - F.  Immunohistochemistry of MT-1/2 in the As3+ Subcutaneous 
Tumors.   
 
Immunohistochemical staining of MT isoforms 1/2 in the Mouse Subcutaneous Tumors from 
the six As3+ UROtsa Transformed Cell lines.  (A) As #1 shows moderate positive staining of 
MT isoforms 1/2 in the less differentiated peripheral cells of tumor nests.  (B) As #2 shows 
less differentiated tumor cells in the invading buds and the outside basal-like cells of tumor 
nests are moderately positive for MT isoforms 1/2.  (C) As #3 shows less differentiated 
basal-like tumor cells that are weak-to-moderately positive for MT isoforms 1/2.  The cells 
with vacuole cytoplasm in the center of tumor nests are negative for MT isoforms 1/2.  (D) 
As #4 shows less differentiated tumor cells in the invading buds and peripheral basal-like 
cells are moderately positive for MT isoforms 1/2.  The relatively well differentiated cells in 
the center of tumor nests are negative for MT isoforms 1/2.  Two keratin pearls are also 
negative for MT isoforms 1/2.  In addition to the moderate staining of MT isoforms 1/2 in the 
less differentiated tumor cells, the spindle tumor stroma cells are strongly positive for MT 
isoforms 1/2.  (E) As #5 shows weak-to-moderate staining of MT isoforms 1/2 in the less 
differentiated tumor cells.  (F) As # 6 shows weak-to-moderate staining of MT isoforms 1/2 
in the less differentiated tumor cells. 
 
All images taken at the magnification of X200. 
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Figure III-14, A - G.  Immunohistochemistry of MT-1/2 in the Cd2+ Subcutaneous 
Tumors.   
 
Immunohistochemical staining of MT isoforms 1/2 in the Mouse Subcutaneous Tumors from 
the seven Cd2+ UROtsa Transformed Cell lines.  (A) Cd #1 shows a moderate staining of MT 
isoforms 1/2 in the less differentiated tumor cells.  (B) Cd #2 shows a weak staining of MT 
isoforms 1/2 in the peripheral less differentiated tumor cells.  (C) Cd #3 shows a weak-to-
moderate staining of MT isoforms 1/2 in the peripheral less differentiated tumor cells.  (D) 
Cd #4 shows a weak-to-moderate staining of MT isoforms 1/2 in the peripheral less 
differentiated tumor cells.  (E) Cd #5 shows a moderate staining of MT isoforms 1/2 in 
invading buds and peripheral less differentiated tumor cells.  (F) Cd #6 shows a weak-to-
moderate staining of MT isoforms 1/2 in the peripheral less differentiated tumor cells.  (G) 
Cd #7 shows a weak-to-moderate staining of MT isoforms 1/2 in the peripheral less 
differentiated tumor cells. 
  
All images taken at the magnification of X200. 
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Figure III-15, A - F.  Immunohistochemistry of MT-3 in the As3+ Subcutaneous 
Tumors.  
  
Immunohistochemical staining of MT isoform 3 in the Mouse Subcutaneous Tumors from 
the six As3+ UROtsa Transformed Cell lines.  (A) As #1 demonstrated diffused and strong 
positive staining for MT isoform 3.  Some less differentiated peripheral cells show weaker 
staining of MT isoform 3, while the Keratin pearls are negative for MT isoform 3.  (B) As #2 
demonstrated diffused and strong positive staining for MT isoform 3.  The tumor stroma cells 
are also positive for MT isoform 3.  (C) As #3 demonstrated diffused and strong positive 
staining for MT isoform 3, but the large cells with vacuole cytoplasm in the center of tumor 
nests show much weaker staining of MT isoform 3.  (D) As #4 demonstrated diffused and 
strong positive staining for MT isoform 3.  The tumor stroma cells are also positive for MT 
isoform 3.  The keratin pearls are almost all negative for MT isoform 3.  (E) As #5 
demonstrated diffused and strong positive staining for MT isoform 3.  The tumor stroma cells 
are also positive for MT isoform 3.  The large cells with vacuole cytoplasm in the center of 
tumor nests show much weaker staining of MT isoform 3.  (F) As #6 demonstrated diffused 
and strong positive staining for MT isoform 3.  The tumor stroma cells are also positive for 
MT isoform 3.  The less differentiated tumor cells show weaker staining of MT isoform 3.  
The keratin material in the center of tumor nests shows much weaker or no staining of MT 
isoform 3. 
 
All images taken at the magnification of X200. 
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Figure III-16, A - G.  Immunohistochemistry of MT-3 in the Cd2+ Subcutaneous 
Tumors.   
 
Immunohistochemical staining of MT isoform 3 in the Mouse Subcutaneous Tumors from 
the seven Cd2+ UROtsa Transformed Cell lines.  (A) Cd #1 demonstrated diffused and strong 
positive staining for MT isoform 3.  The keratin material is almost all negative for MT 
isoform 3.  (B) Cd #2 demonstrated diffused and strong positive staining for MT isoform 3.  
Some stroma cells are also positive for MT isoform 3.  (C) Cd #3 demonstrated diffused and 
strong positive staining for MT isoform 3.  The peripheral less differentiated tumor cells 
show weaker staining.  (D) Cd #4 shows weak-to-moderate staining of MT isoform 3 in the 
peripheral less differentiated tumor cells.  (E) Cd #5 demonstrated diffused and strong 
positive staining for MT isoform 3.  (F) Cd #6 demonstrated diffused and strong positive 
staining for MT isoform 3.  Some tumor stroma cells are also positive for MT isoform 3.  The 
keratin pearls are negative for MT isoform 3.  (G) Cd #7 demonstrated diffused and strong 
positive staining for MT isoform 3.  The peripheral less differentiated tumor cells show a 
weaker staining of MT isoform 3. 
 
All images taken at the magnification of X200. 
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Exposure to Cisplatin Pilot Study. 
 
In order to determine the growth effects of exposure to cisplatin on the Parent 
UROtsa and two As3+ (As #1 and As #5) -and two Cd2+ (Cd #1 and Cd #4) -transformed cell 
lines MTT assays were performed.  In order to determine the growth rate, MTT assays were 
performed on cells dosed at 0.1 µg/mL, 0.25 µg/mL, 0.5 µg/mL, 1.0 µg/mL, and 2.0 µg/mL.  
The growth rates were tested on each day for three days.  The data obtained shows as 
cisplatin increases that growth rates decrease in the UROtsa cell lines (Figure III-17, A-E).  
The higher doses also began to show signs of toxicity and cell death in the higher doses, 
especially on the third day.  To effectively evaluate the effect of cisplatin on MT expression 
the cells need to be replicating in order to uptake the drug.  Therefore, the doses that will be 
used throughout the rest of this study are 0.5 µg/mL and 1.0 µg/mL of cisplatin for two days.  
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Figure III-17, A-E.  Effect of Cisplatin on the Growth Rate of the Parent UROtsa Cell 
Line.  
The growth rates were determined by measuring the capacity of the cells to reduce MTT (3-
(4, 5-dimethylthiazol2-yl)-2, 5-diphenyltetrazolium bromide) to formazan.  The cells were 
allowed to grow for six days and the ability of the cells to reduce MTT was determined every 
day.  All experiments were done in triplicates and shown is the mean absorbance value is 
shown.  (A) Effect of Cisplatin on the Growth Rate of the Parent UROtsa Cell Line.  (B) 
Effect of Cisplatin on the Growth Rate of the UROtsa As #1 -Transformed Cell Line.  (C) 
Effect of Cisplatin on the Growth Rate of the UROtsa As #5 -Transformed Cell Line.  (D) 
Effect of Cisplatin on the Growth Rate of the UROtsa Cd #1 -Transformed Cell Line.  (E) 
Effect of Cisplatin on the Growth Rate of the UROtsa Cd #4 -Transformed Cell Line. 
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Expression of Metallothioneins exposed to Cisplatin in Real Time RT-qPCR. 
 
 The expression of MT isoforms was determined in Parent UROtsa cells and two As3+ 
(As #1 and As #5) -and two Cd2+ (Cd #1 and Cd #4) -transformed cell lines that were 
exposed to various doses of the chemotherapeutic drug cisplatin by real time RT-qPCR and 
Western Blot analysis.  For this study As #1 and Cd #1 were picked because they can from 
intraperitoneal tumors, while As #5 and Cd #4 cannot form intraperitoneal tumors.  This 
allows us to see if there is a difference in MT expression after exposure to cisplatin in all five 
cell lines.  All five cell lines were dosed with 0.5 µg/mL and 1.0 µg/mL of cisplatin near 
confluency and the cells were harvested after Day #1 (24-hours) and Day #2 (48-hours).  
Real time RT-qPCR was performed on all six MT isoforms (MT-1A, MT-1E, MT-1F, MT-
1X, MT-2A and MT-3) in the Parent UROtsa and the As3+-and Cd2+-transformed cell lines.   
In the Parental cell line, there was no significant change in the expression levels of 
MT isoform 1A (Figure III-18, A).  For the As3+-transformed cell lines, there was a 
significant increase in the expression of MT isoform 1A in As #1, when the cells were treated 
with 1.0 µg/mL of cisplatin for Day #1 (24-hours) (Figure III-18, B).  There was no 
significant change in expression levels of MT isoform 1A in As #5 (Figure III-18, C).  For 
Cd #1, the expression of MT isoform 1A decreased after Day #2 (48-hours) treatment with 
cisplatin (Figure III-18, D), however no change in expression levels were noted for Cd #4 
(Figure III-18, E).   
 The expression of MT isoform 1E was decreased in the Parental UROtsa cell line 
when treated with 1.0 µg/mL of cisplatin for Day #1 (24-hours).  However, after Day #2 (48-
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hours) there was no difference in expression between the control and the treated cells (Figure 
III-19, A).  For the As3+-and Cd2+ -transformed cell lines, for As #1, there was a decrease in 
expression of MT isofrom1E in cells exposed to cisplatin treated cells for Day #1 (24-hours) 
and this decrease was also seen after Day #2 (48-hours) exposure (Figure III-19, B).  
However, for As #5, there was no significant change in the level of expression of MT 
isoform 1E even after Day #2 (48-hours) of exposure (Figure III-19, C).  For Cd#1 and Cd#4, 
exposure to cisplatin at both doses resulted in a decrease in the expression of MT isoform 1E 
and this decrease persisted throughout the Day #2 (48-hours) exposure (Figures III-19, D-E).   
 The expression of MT isoform1F showed a decrease after Day #1 (24-hours) 
exposure to cisplatin at 1.0 µg/mL and after Day #2 (48-hours) of exposure.  There was also 
a decrease in expression at both 0.5 and 1.0 µg/mL of cisplatin (Figure III-20, A).  For the 
As3+-transformed cell lines, As #1 and As #5, there was decrease in expression of MT 
isoform 1F at both doses after Day #1 (24-hours) exposure and this decrease persisted up to 
Day #2 (48-hours) of treatment (Figures III-20, B-C).  The expression of MT isoform 1F in 
the Cd2+-transformed cell line Cd #1 was similar to the untreated controls, whereas for Cd 
#4, there was a decrease in expression at both doses up to Day #2 (48-hours) of treatment 
(Figures III-20, D-E).    
 The basal expression of MT isoform 1X was low in all the five cell lines.  For the 
Parent UROtsa cells, treatment with cisplatin at doses of 0.5 µg/mL and 1.0 µg/mL resulted 
in a decrease in expression of MT isoform 1X at Day #2 (48-hours).  There was no effect of 
cisplatin at either of the doses after Day #1 (24-hours) of exposure (Figure III-21, A).  For 
the As3+-transformed cell lines, there was a decrease in expression of MT isoform 1X after 
Day #2 (48-hours) of treatment with 1.0 µg/mL of cisplatin (Figures III-21, B-C).  For Cd #1, 
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there was a decrease in expression after Day #1 (24-hours) and Day #2 (48-hours) of 
treatment with both 0.5 and 1.0 µg/mL of cisplatin.  For Cd #4, there was not effect on the 
expression of MT isoform 1X after treatment with cisplatin (Figures III-21, D-E).    
 Exposure to cisplatin had no effect on the expression levels of MT isoform 2A in the 
Parent UROtsa cells (Figure III-22, A).  For the As3+-transformed cell lines, there was a 
decrease in expression of MT isoform 2A in As #1, whereas exposure to cisplatin had no 
effect on the expression levels of MT isoform 2A in As #5 (Figures III-22, B-C).  The 
expression of MT isoform 2A decreased in both Cd #1 and Cd #4 when the cells were 
exposed to cisplatin for Day #1 (24-hours) and Day #2 (48-hours) (Figures III-22, D-E).     
 The final MT isoform that was evaluated through real time RT-qPCR was MT 
isoform 3.  The basal expression of MT isoform 3 in the Parent UROtsa and the transformed 
cell lines is very low and treatment with cisplatin had no effect on the expression levels of 
MT isoform 3 in the Parent UROtsa as well as the transformed cell lines (Figures III-23, A-
E).  
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Figure III-18, A-E.  Expression of MT-1A in UROtsa Cell Line exposed to Cisplatin.  
Real-time RT-qPCR analysis of MT isoform 1A mRNA levels that were treated with 0.0 
µg/mL, 0.5 µg/mL and 1.0 µg/mL of cisplatin over a two day treatment.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ±SEM (n=3) for the 
Parent UROtsa and UROtsa cell lines transformed with As3+ or Cd2+.  (A) Expression of MT-
1A in UROtsa Cell Line exposed to cisplatin.  (B) Expression of MT-1A in As #1 
Transformed Cell Line exposed to cisplatin.  (C) Expression of MT-1A in As #5 
Transformed Cell Line exposed to cisplatin.  (D) Expression of MT-1A in Cd #1 
Transformed Cell Line exposed to cisplatin.  (E) Expression of MT-1A in Cd #4 
Transformed Cell Line exposed to cisplatin.   
 
For statistically significant changes in comparison to the Control (0.0 µg/mL) Day #1 or 
Control (0.0 µg/mL) Day #2, respectively.  
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
 
 
 
 
 
50 
 
 
      
      
 
51 
 
Figure III-19, A-E.  Expression of MT-1E in UROtsa Cell Line exposed to Cisplatin.  
Real-time RT-qPCR analysis of MT isoform 1E mRNA levels that were treated with 0.0 
µg/mL, 0.5 µg/mL and 1.0 µg/mL of cisplatin over a two day treatment.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ±SEM (n=3) for the 
Parent UROtsa and UROtsa cell lines transformed with As3+ or Cd2+.  (A) Expression of MT-
1E in UROtsa Cell Line exposed to cisplatin.  (B) Expression of MT-1E in As #1 
Transformed Cell Line exposed to cisplatin.  (C) Expression of MT-1E in As #5 
Transformed Cell Line exposed to cisplatin.  (D) Expression of MT-1E in Cd #1 
Transformed Cell Line exposed to cisplatin.  (E) Expression of MT-1E in Cd #4 
Transformed Cell Line exposed to cisplatin.   
 
For statistically significant changes in comparison to the Control (0.0 µg/mL) Day #1 or 
Control (0.0 µg/mL) Day #2, respectively.  
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Figure III-20, A-E.  Expression of MT-1F in UROtsa Cell Line exposed to Cisplatin.  
Real-time RT-qPCR analysis of MT isoform 1F mRNA levels that were treated with 0.0 
µg/mL, 0.5 µg/mL and 1.0 µg/mL of cisplatin over a two day treatment.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ±SEM (n=3) for the 
Parent UROtsa and UROtsa cell lines transformed with As3+ or Cd2+.  (A) Expression of MT-
1F in UROtsa Cell Line exposed to cisplatin.  (B) Expression of MT-1F in As #1 
Transformed Cell Line exposed to cisplatin.  (C) Expression of MT-1F in As #5 Transformed 
Cell Line exposed to cisplatin.  (D) Expression of MT-1F in Cd #1 Transformed Cell Line 
exposed to cisplatin.  (E) Expression of MT-1F in Cd #4 Transformed Cell Line exposed to 
cisplatin.   
 
For statistically significant changes in comparison to the Control (0.0 µg/mL) Day #1 or 
Control (0.0 µg/mL) Day #2, respectively.  
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Figure III-21, A-E.  Expression of MT-1X in UROtsa Cell Line exposed to Cisplatin.  
Real-time RT-qPCR analysis of MT isoform 1X mRNA levels that were treated with 0.0 
µg/mL, 0.5 µg/mL and 1.0 µg/mL of cisplatin over a two day treatment.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ±SEM (n=3) for the 
Parent UROtsa and UROtsa cell lines transformed with As3+ or Cd2+.  (A) Expression of MT-
1X in UROtsa Cell Line exposed to cisplatin.  (B) Expression of MT-1X in As #1 
Transformed Cell Line exposed to cisplatin.  (C) Expression of MT-1X in As #5 
Transformed Cell Line exposed to cisplatin.  (D) Expression of MT-1X in Cd #1 
Transformed Cell Line exposed to cisplatin.  (E) Expression of MT-1X in Cd #4 
Transformed Cell Line exposed to cisplatin.   
 
For statistically significant changes in comparison to the Control (0.0 µg/mL) Day #1 or 
Control (0.0 µg/mL) Day #2, respectively.  
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Figure III-22, A-E.  Expression of MT-2A in UROtsa Cell Line exposed to Cisplatin.  
Real-time RT-qPCR analysis of MT isoform 2A mRNA levels that were treated with 0.0 
µg/mL, 0.5 µg/mL and 1.0 µg/mL of cisplatin over a two day treatment.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ±SEM (n=3) for the 
Parent UROtsa and UROtsa cell lines transformed with As3+ or Cd2+.  (A) Expression of MT-
2A in UROtsa Cell Line exposed to cisplatin.  (B) Expression of MT-2A in As #1 
Transformed Cell Line exposed to cisplatin.  (C) Expression of MT-2A in As #5 
Transformed Cell Line exposed to cisplatin.  (D) Expression of MT-2A in Cd #1 
Transformed Cell Line exposed to cisplatin.  (E) Expression of MT-2A in Cd #4 
Transformed Cell Line exposed to cisplatin.   
 
For statistically significant changes in comparison to the Control (0.0 µg/mL) Day #1 or 
Control (0.0 µg/mL) Day #2, respectively.  
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Figure III-23, A-E.  Expression of MT-3 in UROtsa Cell Line exposed to Cisplatin.  
Real-time RT-qPCR analysis of MT isoform 3 mRNA levels that were treated with 0.0 
µg/mL, 0.5 µg/mL and 1.0 µg/mL of cisplatin over a two day treatment.  The mRNA levels 
were normalized to β-Actin and are shown as relative mRNA levels ±SEM (n=3) for the 
Parent UROtsa and UROtsa cell lines transformed with As3+ or Cd2+.  (A) Expression of MT-
3 in UROtsa Cell Line exposed to cisplatin.  (B) Expression of MT-3 in As #1 Transformed 
Cell Line exposed to cisplatin.  (C) Expression of MT-3 in As #5 Transformed Cell Line 
exposed to cisplatin.  (D) Expression of MT-3 in Cd #1 Transformed Cell Line exposed to 
cisplatin.  (E) Expression of MT-3 in Cd #4 Transformed Cell Line exposed to cisplatin.   
 
For statistically significant changes in comparison to the Control (0.0 µg/mL) Day #1 or 
Control (0.0 µg/mL) Day #2, respectively.  
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.001 
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Expression of Metallothioneins exposed to Cisplatin Western Blot Analysis.  
 
Western blot analysis is an important technique used in cell and molecular biology.  
Through western blot analysis, scientists are able to identify specific protein concentrations 
from complex mixtures.  This technique uses three elements to identify protein concertation, 
first separation by size, second transfer to a solid support, and third proper target antibodies.  
In this project the western blots were probed for MT isoforms 1/2 (E9 Clone) followed by β-
Actin as a control.  MT isoforms 1/2 is a monoclonal antibody that encompasses all of the 
MT isoform 1 and MT isoform 2.  The antibody was purchased from DAKO.  More specific 
details described in the Methods and Materials.     
The cells were subjected to an acute cisplatin exposure before being harvested.  More 
specific details on the acute cisplatin exposure as described in the Methods and Materials.  
The cells lines that were tested were As #1, As #5, Cd #1, and Cd #4, along with the Parent 
UROtsa cell line.  There is not a single real time RT-qPCR graph that aligns with each 
western blot analysis due to the fact that the western blot analysis antibody encompasses all 
of the MT isoform 1 and MT isoform 2.  On the other hand, the real time RT-qPCR primers 
that were used were MT isoform specific, therefore we have five real time RT-qPCR graphs 
that all align with each western blot analysis.  
Western blot analysis performed on the Parent UROtsa cell line showed that there 
was a decrease in the expression levels of MT protein when the cells were exposed to 
cisplatin.  This decrease was visible at 0.5 µg/mL and 1.0 µg/mL doses of cisplatin at both 
Day #1 and Day #2 (Figure III-24).  The cells were striped and re-probed for β-Actin.  
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The expression of MT protein was also determined for the As3+-transformed cell 
lines, As #1 and As #5.  The data showed that there was an increase in the expression of MT 
protein in As #1 at 0.5 µg/mL and 1.0 µg/mL doses of cisplatin.  However, at Day #2, the 
expression was still increased in the cells exposed to 0.5 µg/mL of cisplatin.  Additionally, 
the cells that were exposed to 1.0 µg/mL of cisplatin had expression levels similar to the 
untreated control cells (Figure III-25).  For As #5, there was an increase in expression of MT 
protein on Day #1 at 0.5 µg/mL.  The increased expression as a result to the exposure to 
cisplatin remained elevated both days of the acute cisplatin exposure (Figure III-26).  The 
cells were striped and re-probed for β-Actin.  
The effect of cisplatin exposure on MT levels were also determined for the Cd2+-
transformed cell lines, Cd #1 and Cd #4.  As seen in Figure III-27, there was a decrease in 
expression of MT when the cells were exposed to 0.5 µg/mL and 1.0 µg/mL of cisplatin on 
Day #1 and Day #2.  The expression of MT protein in Cd #4 was opposite to what was seen 
in Cd #1.  The exposed cells showed an increase in expression at 0.5 µg/mL and 1.0 µg/mL 
on Day #1, as well as, Day #2 (Figure III-28).  The cells were striped and re-probed for β-
Actin.  
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Figure III-24.  Expression of MT-1/2 in the Parent UROtsa Cells exposed to Cisplatin. 
 
The Western blots analysis were probed for MT isoforms 1/2 (E9 Clone), then striped and re-
probed for β-Actin as a control.  MT isoforms 1/2 is a monoclonal antibody that encompasses 
all of the MT isoform 1 and MT isoform 2.  The #’s identify the independent cells lines that 
were isolated by the exposure of UROtsa cells to either As3+ or Cd2+.  These numbers are 
consistent identifiers throughout the paper. 
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Figure III-25.  Expression of MT-1/2 in As #1 Cells exposed to Cisplatin. 
 
The Western blots analysis were probed for MT isoforms 1/2 (E9 Clone), then striped and re-
probed for β-Actin as a control.  MT isoforms 1/2 is a monoclonal antibody that encompasses 
all of the MT isoform 1 and MT isoform 2.  The #’s identify the independent cells lines that 
were isolated by the exposure of UROtsa cells to either As3+ or Cd2+.  These numbers are 
consistent identifiers throughout the paper. 
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Figure III-26.  Expression of MT-1/2 in As #5 Cells exposed to Cisplatin.  
 
The Western blots analysis were probed for MT isoforms 1/2 (E9 Clone), then striped and re-
probed for β-Actin as a control.  MT isoforms 1/2 is a monoclonal antibody that encompasses 
all of the MT isoform 1 and MT isoform 2.  The #’s identify the independent cells lines that 
were isolated by the exposure of UROtsa cells to either As3+ or Cd2+.  These numbers are 
consistent identifiers throughout the paper. 
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Figure III-27.  Expression of MT-1/2 in Cd #1 Cells exposed to Cisplatin. 
 
The Western blots analysis were probed for MT isoforms 1/2 (E9 Clone), then striped and re-
probed for β-Actin as a control.  MT isoforms 1/2 is a monoclonal antibody that encompasses 
all of the MT isoform 1 and MT isoform 2.  The #’s identify the independent cells lines that 
were isolated by the exposure of UROtsa cells to either As3+ or Cd2+.  These numbers are 
consistent identifiers throughout the paper. 
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Figure III-28.  Expression of MT-1/2 in Cd #4 Cells exposed to Cisplatin.  
 
The Western blots analysis were probed for MT isoforms 1/2 (E9 Clone), then striped and re-
probed for β-Actin as a control.  MT isoforms 1/2 is a monoclonal antibody that encompasses 
all of the MT isoform 1 and MT isoform 2.  The #’s identify the independent cells lines that 
were isolated by the exposure of UROtsa cells to either As3+ or Cd2+.  These numbers are 
consistent identifiers throughout the paper. 
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CHAPTER IV.   
 
DISCUSSION. 
 
Metallothionein Expression Levels.   
 
This study was motivated by the recent increase in literature referencing an in-vivo 
relationship between resistance to cisplatin and MT isoform expression levels.  MT are a 
well-known and highly studied cysteine-rich, low molecular weight family of intracellular 
proteins that bind to heavy metals with high affinity (Andrews, 2000).  Human bladder 
cancer was the first cancer that found industrial carcinomas were determined to play a major 
role in disease causation (Zhou, et al., 2006).  This was observed by Rehn in 1895 (Dietrich 
& Dietrich, 2001).  He suggested there was a link between exposure to aromatic amines and 
development of bladder cancer in factory workers (Rehn, 1895).  This now extends to the 
present and confirms that exposure to the human carcinogens As+3 and Cd+2 occurs via 
environmental exposure, cigarette smoking, industrialization, and contaminated water 
sources (Somji, et al., 2008).   
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To further study the effects of As+3 and Cd+2 our laboratory transformed the UROtsa 
cell line with them.  The UROtsa cell morphology aligns with primary urothelial cells 
growing in tightly packed colonies allowing investigation into the preliminary phase of 
development, making it an ideal cell line to study early bladder cancer (Rossi, et al., 2001).  
Our laboratory has exposed the immortalized UROtsa cell line to As3+ or Cd2+ in order to 
establish an in-vitro cell culture model that is representative of the mechanisms involved in 
early bladder cancer.  UROtsa cells can serve as a valuable adjunct for studying the human 
urothelium in general and the stress response in particular (Rossi, et al., 2001).  Our 
laboratory has even further characterized the As3+ -and Cd2+ -transformed cell lines to 
express genes similar to the basal subtype of muscle invasive bladder cancer (Hoggarth, et 
al., 2018) 
The first goal of this study is to determine the expression level of six MT isoforms in 
the Parent UROtsa cell line and the independently derived As+3 -and Cd+2 -transformed cell 
lines.  To assess the expression of the MT isoforms, real time RT-qPCR analysis was 
conducted.  Our real time RT-qPCR data demonstrated that the MT isoforms showed a 
decreased expressed in the UROtsa As3+ -and Cd2+ -transformed cell lines compared to the 
Parent UROtsa with a few exceptions.  IHC analysis of the tumor transplants generated by 
the subcutaneous injection of the transformed cell lines into immune-compromised mice 
showed that there is moderate or weak-to-moderate staining of MT isoforms 1/2 in the 
subcutaneous tumors.  However, the staining for MT isoform 3 was strong and diffuse with 
weaker staining in the less differentiated peripheral cells.  This data contradicts the in-vitro 
data where MT isoform 3 is not expressed in the transformed cell lines.  It seems that the 
expression of MT isoform 3 is turned off in-vitro and in-vivo there is increase expression of 
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MT isoform 3.  This agrees with other studies which have shown an increase expression of 
MT isoform 3 in human bladder tumors.  MT isoform 3 is known to decrease the growth rate 
of cells and it is possible that the cells in-vitro are tuning off the expression since it inhibits 
the growth of the cells.   
Decreased expression of the MT isoforms 1/2 isoforms in the As3+ -and Cd2+ -
transformed cell lines can be explained by several properties that have been cited within the 
literature.  As described previously, MT normal role provides minimal detoxification by 
uptake, transport, and regulation of metals in cellular biological systems and tissues (Nagel 
and Vallee, 1995).  However, each of the MT isoforms are regulated independently of each 
other and can have unique expressional changes from the presence of metals, stress 
hormones, cytokines, reactive oxygen species (ROS), and chemicals (Laukens, 2009).  The 
literature has shown that ROS generated during the inflammatory response may activate or 
repress MT expression, as well as, specific metal response elements associated with second-
messenger protein kinase pathways (Ren and Smith, 1995).  It is possible that exposure to the 
heavy metals during the transformation process disrupted redox homeostasis.  Under 
physiologic conditions, the balance between generation and elimination of ROS/RNS 
maintains the proper function of redox-sensitive signaling proteins (Trachootham, Lu, 
Ogasawara, Rivera-Del Valle, & Huang, 2008).  Normally, the redox homeostasis ensures 
that the cells respond properly to endogenous and exogenous stimuli.  However, when the 
redox homeostasis is disturbed, oxidative stress may lead to aberrant cell death 
(Trachootham, Lu, Ogasawara, Rivera-Del Valle, & Huang, 2008).  This may explain why 
we see a decrease expression of the six MT isoforms in the As3+ -and Cd2+ -transformed cell 
71 
 
lines but not in the Parent UROtsa cell line.  ROS and cellular oxidant stress are known 
regulators of cancer cells (Qiu, et al., 2015).   
 
Metallothionein Expression Levels in Cells exposed to Cisplatin. 
 
Cisplatin is a platinum complex that consists of two carrier ligands of ammonia and 
two leaving groups of chloride.  Literature suggest that there is a growing number of patients 
that are developing a resistance to cisplatin (Köberle and Piee-Staffa, 2011).  MT 
overexpression may predict unfavorable survival in bladder cancer patients in those treated 
with cisplatin chemotherapy (Wulfing, et. al., 2007).  It is estimated that about 68.0% 
of bladder tumors will respond to cisplatin-based chemotherapy but only 30.0% will have a 
durable response (Wood, Klein, Fair, & Chaganti, 1993).  In a human study that focused on 
TCC of the bladder with IHC methods showed all of the tumors stained positive for MT.  The 
MT staining was localized almost exclusively to the cytoplasm (Bahnason, et. al., 1991).  
Other patient studies also demonstrate the survival rate is significantly poorer if tumors are 
expressing high levels MT (Wulfing, et. al., 2007).  Thus, due to the increases resistance that 
is being developed against cisplatin, the effectiveness of the drug is decreasing resulting in a 
higher recurrence rate.  
The second goal of this study is to determine the expression levels of MT in the 
Parent UROtsa, two As+3 –and two Cd+2 -transformed cell lines when they are acutely 
exposed to various concentrations of the chemotherapy drug, cisplatin.  The real time RT-
qPCR analysis consisted of mRNA levels that were treated with either 0.0 µg/mL (control), 
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0.5 µg/mL, or 1.0 µg/mL of cisplatin over a two-day (48-hour) treatment period.  Overall, the 
results showed that the expression of MT decreased in response to cisplatin.  Western blot 
analysis was also performed to determine the total levels of MT isoforms 1/2.  The 
expression levels of the MT isoforms 1/2 protein varied between cell lines, however 
treatment with cisplatin showed a decrease in the level of total MT isoforms 1/2 protein.  
This suggests that it is possible that the cancer cells may develop a mechanism to decrease 
MT levels in response to cisplatin exposure as this may aid in the growth and metastasis of 
the tumor.  The mechanism by which the malignant cells decrease the expression of MT 
isoform 1/2 in response to cisplatin is not known at this time.  
The mechanism by which bladder cancer develops a resistance to the chemotherapy 
drug cisplatin is not fully known, however literature suggests that an over expression of MT 
play a major role (Hagrman, Goodisman, Dabrowiak, & Souid, 2003).  Due to the fact that 
cisplatin is a platinum complex it is suspected that it is being regulated out by the normal 
function of the MT isoforms (Gelasco & Lippard, 1998).  Therefore the overexpression of 
MT seen in the in-vivo tumors correlates to the resistance of the drug in patients.  Our results 
show that there was a decreased expression of the six MT isoforms in the As3+ -and Cd2+ -
transformed cell lines.  This decrease in MT expression may disrupt the normal cellular 
redox within the cells, thus promoting the transformation process.   
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Significance. 
 
The overall goal of this study was to determine if the expression levels of the six MT 
isoforms corresponds to resistance in patients to treatment with cisplatin.  The expectation 
that there is a relationship was based on several factors shown within literature that defines 
the relationship between MT expression and cisplatin resistance in-vivo.  Our in-vitro results 
show that were exposure to As3+ or Cd2+ decreases the expression of MT.  This decrease in 
MT expression may disrupt the normal cellular redox within the cells, thus promoting the 
transformation process (Trachootham, Lu, Ogasawara, Rivera-Del Valle, & Huang, 2008).  
Normally, the redox homeostasis ensures that the cells respond properly to endogenous and 
exogenous stimuli.  However, in this case the disruption may mean the decreased expression 
levels of the MT isoforms will be less likely to interfere with the cisplatin.  This would mean 
that the patient would have a reduced chance of developing resistance to cisplatin and a 
higher patient prognosis.  In addition, exposure to cisplatin in the presence of reduced of MT 
expression may have implications in the treatment of bladder cancer with this drug.  
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Authenticity Statement. 
 
To our knowledge no studies have been done to date to evaluate the six MT isoforms 
used throughout this project to determine the expression in correlation to the resistance of 
cisplatin in the Parent UROtsa and the As3+ -and Cd2+ -transformed cell lines.  In this study, 
analyses were performed on the immortalized UROtsa cell lines, As3+ -and Cd2+-transformed 
cell lines and on mouse heterotransplant tumors samples to evaluate the expression of six MT 
isoforms.  Further analyses were performed on the UROtsa cell lines, two As3+ -and two 
Cd2+-transformed cell lines that were acutely exposed to cisplatin.  The overall goal was to 
attempt to better characterize the mechanisms in play between the MT and the development 
to cisplatin in bladder cancer.  In many studies, there are evidence suggesting that increased 
expression of MT correlates to cisplatin resistance and poor patient prognosis, however 
further studies are necessary to correlate the data with clinical outcomes.   
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APPENDIX A. 
 
Abbreviations. 
 
ACS American Cancer Association  
ANOVA One-Way Analysis of Variance   
As3+ Arsenite 
BCA Bicinchoninic Acid Assay 
BCA Bicinchoninic Acid Assay 
BFD Blackfoot Disease 
BFD Blackfoot Disease 
BSA Bovine Serum Albumin 
C Carbon 
Cd2+ Cadmium 
CDC Center for Disease Control and Prevention 
CdCl2 Cadmium Chloride 
cDNA Complementary DNA 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
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Cisplatin Cis-diamminediechloroplatinum(II), CDDP 
CNS Central Nervous System 
Co Cobalt 
CO2 Carbon Dioxide 
Cu Copper 
DAB 3,3'-Diaminobenzidine 
DMEM Dulbecco’s Modified Eagle Medium 
DNA Deoxynucleic Acid 
FCS Fetal Calf Serum  
Fe Iron 
GHS Glutathione 
H Hydrogen 
H20 Water 
Hg Mercury 
IARC International Agency for Research on Cancer 
IHC Immunohistochemistry 
MCL Maximum Containment Level 
mRNA Messenger Ribonucleic Acid 
MT Metallothionein  
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromidefor 
N Nitrogen 
Na Sodium 
NaAsO2 Sodium Arsenite 
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NaCl Sodium Chloride 
NH3 Ammonia 
Ni Nickel 
NTP National Toxicology Program 
O Oxygen 
Pb Lead 
PBS Phosphate Buffered Saline  
PMSF Phenylmethane Sulfonyl Fluoride 
Pt Platinum 
PVD Peripheral Vascular Disease 
PVD Peripheral Vascular Disease 
PVDF Polyvinylidene Difluoride 
rcf Relative Centrifuge Force 
RIPA Radioimmunoprecipitation Assay Buffer 
RT-qPCR Real-Time Quantitative Polymerase Chain Reaction     
S2- Sulfide 
Se Selenium 
SEM Standard Error of the Mean 
SV40 Simian Vacuolating Virus 40 or Simian Virus 40 
T-antigen Tumor Antigen 
TBS Tris-Buffered Saline 
TBS-T TBS-Tween 
TCC Transitional Cell Carcinomas 
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Zn Zinc 
β-Actin Beta-Actin 
β-Mercaptoethanol Beta-Mercaptoethanol  
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Units of Measurement. 
 
AMP Ampere 
cm2 Centimeters Squared 
kDa KiloDalton 
L Liter 
mL Milliliter (10-3 Liter) 
mM Millimolar (10-3 Mole/Liter) 
mm Millimeter (10-3 Meter) 
rcf Relative Centrifugal Force 
V Volts 
˚C Degrees Celsius 
µg Microgram (10-9 Gram) 
µM Micromolar (10-6 Mole/Liter) 
µm Micrometer (10-6 Meter) 
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APPENDIX B. 
 
Buffers and Solution Recipes. 
 
          20/12 Media 
 250.0 mL DMEM (Sigma Aldrich #D5523-10) 
 250.0 mL Nutrient Mixture F12 Ham (Sigma Aldrich #N6760-10) 
 5.0 mL L.Glutamine (Gibco #25030-81) 
 5.0 mL Recombinant Human E.G.F. Lyophilized (Sigma #PHG0311) 
 0.5 mL ITS Premix Universal Culture Supplement (Corning #354350) 
 0.5 mL T3 (Sigma #T6397) 
 0.5 mL HC (Gibco #EL0013) 
          Dulbecco’s Modified Eagle Medium (DMEM) 
 4945.0 mL Milli Q Water 
 5.0 Bottles DME Powder (Sigma #D5523-10) 
 50.0 mL Penicillin-Streptomycin (Pen-Strep) (Gibco #15140-122) 
 5.0 m L  FungiZone (Gibco #15920-018) 
 18.5 g Na-Bicarbonate (Fisher Chemicals #BP328-500) 
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          F-12 Media  
 4945.0 mL Milli Q Water 
 1.0 Bottle Nutrient Mixture F-12 HAM (Sigma #N6760-10) 
 5.0 mL FungiZone (Gibco #15920-018) 
 50.0 m L Penicillin-Streptomycin (Pen-Strep) (Gibco #15140-122) 
 5.88 g Na-Bicarbonate (Fisher Chemicals #BP328-500) 
          Phosphate Buffered Saline (PBS) 
 5.0 L Milli Q Water 
 42.5 g NaCl (Sigma Aldrich #S9888-2.5KG) 
 0.60 g Na2HPO4 (Dibasic) (Fisher Chemicals #BP332-500) 
 0.25 g NaH2PO4 (Monobasic) (Fisher Chemicals #BP329-500) 
          0.5X TAE Buffer Molecular Biology Grade 
 500.0 mL Milli Q Water 
 25.0 mL 10X TBE (BioRad #170-6435) 
          2.0 % Large Agarose Gel 
 65.0 mL 0.5X TBE 
 1.3 g Agarose (Fisher BioReagents #BP1356-100) 
 1.62 µL Ethidium Bromide (ThermoFisher Scientific #15585011) 
          2.0 % Small Agarose Gel 
 40.0 mL 0.5X TBE 
 0.4 g Agarose (Fisher BioReagents #BP1356-100) 
 1.0 µL Ethidium Bromide (ThermoFisher Scientific #15585011) 
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          1X Tris/Glycine/SDS Solution (Running Buffer) 
 675.0 mL Milli Q Water 
 75.0 mL 10X Tris/Glycine/SDS Solution (BioRad #161-0732) 
          1X Tris Buffered Saline (TBS) 
 450.0 mL Milli Q Water 
 50.0 mL 10X TBS (BioRad #170-6435) 
          1X Tris Buffered Saline - 1.0 % Tween (TBST) 
 450.0 mL Milli Q Water 
 50.0 mL 10X TBS (BioRad #170-6435) 
 5.0 mL Tween (Sigma #P1379-500) 
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APPENDIX C. 
 
Real Time RT-qPCR and Ct Cycle Introduction. 
 
The general reaction system of conventional PCR is the same for real-time PCR, 
the only difference is that the accumulation of product is monitored within the reaction 
tube at the end of each PCR cycle.  The DNA is detached by fluorescence of the 
intercalating dye, such as SYBR green.  Much like ethidium bromide, when this dye 
intercalates with double stranded DNA the intensity of the fluorescence is dramatically 
increased.  Primers attach to the ends of the PCR product.  The upper primer (sense 
primer) has the same sequences as that found in the RNA and the lower primer (antisense 
primer) or downstream primer has a sequence that is the reverse complement of the 
corresponding sequences in the RNA.  
 Amplification should be 90% or better in an optimized reaction.  This means that 
the amount of DNA should nearly double at every cycle.  Mispriming may occur when 
sequence site in the population of DNA molecules are just a few base pairs off from the 
primer sequence.  One increases the temperature so that only the perfectly matched 
sequences will be bound by the primer which fixes the misprinting problem.  There is a 
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window of optimal temperature for PCR, where at temperatures above this window, 
amplification efficiency is falls back off due to lack of priming, and temperatures below 
this window, results in Mispriming, giving some other amplified products.  The size of 
this window is determined by the differences in the sequence at the potential primer 
binding sites.  Large sequence differences should yield a large range of optimal PCR 
annealing temperatures.  Other factors that determine the temperature of optimal PCR are 
the length and the GC content of the primers: higher GC content or longer primers will 
increase primer binding.  We have a primer design software called “Oligo” that searches 
sequences for optimal primers.  This program will indicate what temperatures should 
work, but usually verification by a wet PCR run is required to establish the optimal 
temperature condition.  Sometimes one needs to change the annealing temperature 
despite all theoretical calculations.  
 What is it about the real-time techniques that gives it such an advantage?  In real-
time PCR, the threshold cycle is measured and not the level of product at later stages of 
amplification.  The threshold cycle number is not influences by impurities with the 
sample unlike most other types of conventional PCR.  This has been illustrated by the 
inform PCR experiment shown below where the same template concentration was 
amplified in 3 separate wells of the instrument.  In this graph, all traces cross the 
threshold florescence’s line at nearly the same place, whereas, at later stages of 
amplification, the traces diverge from each other.  It is this quality of technique, 
measuring threshold cycle number that allows one to make standard curves.  In 
conventional PCR, standards cannot be run for the amplification efficiency in the later 
stages of CR slightly different among the individual sample tubes.  
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A typical profile of amplifications: it looks like a sigmoid curve.  It starts with 
increasing slope which represents the exponential phase of the curve, followed by a linear 
phase where amplification efficiency is starting to fall off, and finally a gradual leveling 
off to a plateau phase.  Most of the time when this is published, the fluorescence is 
plotted on a log graph which makes it look more impressive.  Not that all the samples 
with higher amounts of template are amplified first.  
How is a standard curve generated?  Quantitated amounts of template, serially 
diluted are added to each tube and the threshold cycle (Ct) number is measured.  For the 
standard curve, the threshold cycle number is plotted against the log of the template input 
(see figure below).  The slope of the standard curve is negative, and the amplification 
efficiency can be calculated from this.  Efficiency (expressed as a decimal, 0.1 equals 
100%) = [10E (-1/slope)]-1.  The efficiency is 100% when the slope is -3.32.  The slope 
expresses the fact that it takes3.32 more cycles of PCR to reach the threshold when the 
samples is diluted1-10 and amplification is 100%.  Perfect amplification efficiency 
indicates that the product amount will double at each cycle, therefor at 3 cycles the 
product increase 9-fold, at 4 cycles, 16-fold, and 10-fold in calculated to by a 3.32 cycles.  
In the real world efficiency is often less due to random error and impurities, and since the 
slope is essentially calculated by the linear regression using the least-squares approach, 
the slope can occasionally be less than -3.32 just from random errors in producing 
standard curves.  This means that greater than 100% is also possible.  Generally when 
things are working 80 to 120% efficiencies can be seen and often it can be limited to the 
range of 90 to 110 %.  Much higher efficiencies are often caused by contamination where 
the lower concentration standards have reach a limited threshold cycle (further dilution 
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does not yield a higher threshold cycle number).  This simple bends the curve to a flatter 
configuration leading to a less negative slope in the curve.  This is fixed by simply 
deleting the standard from the curve.  
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